<DOC>
	<DOCNO>NCT00058292</DOCNO>
	<brief_summary>RATIONALE : Radiolabeled monoclonal antibody yttrium Y90 ibritumomab tiuxetan locate cancer cell deliver radioactive cancer-killing substance without harm normal cell . Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining yttrium Y90 ibritumomab tiuxetan chemotherapy autologous stem cell transplant may allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : This phase I trial study well give yttrium Y90 ibritumomab tiuxetan high-dose chemotherapy follow autologous stem cell transplant work treat patient relapsed refractory non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Radiolabeled Monoclonal Antibody Therapy High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant Treating Patients With Relapsed Refractory Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose yttrium Y 90 ibritumomab tiuxetan , term absorb radiation critical organ , administer high-dose chemotherapy follow autologous peripheral blood stem cell transplantation patient relapse refractory B-cell non-Hodgkin 's lymphoma . - Determine whether residual radioactivity detect time stem cell reinfusion affect reinfused cell delays engraftment patient treat regimen . - Determine duration response survival patient treat regimen . OUTLINE : This dose-escalation study yttrium Y 90 ibritumomab tiuxetan ( IDEC-Y2B8 ) . - Radioimmunotherapy : Patients receive rituximab IV follow indium In 111 ibritumomab tiuxetan ( image ) IV 10 minute day -22 . Patients receive rituximab IV IDEC-Y2B8 IV 10 minute day -14 . Cohorts 3-6 patient receive escalate dos IDEC-Y2B8 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 3 6 patient experience dose-limiting toxicity . - High-dose conditioning regimen : Patients receive BEAM chemotherapy comprise carmustine IV 2 hour day -6 , etoposide IV 2 hour twice daily cytarabine IV 1 hour twice daily day -5 -2 , melphalan IV 1 hour day -1 . - Autologous stem cell transplantation : Autologous peripheral blood stem cell reinfused day 0 . Patients receive filgrastim ( G-CSF ) subcutaneously daily begin day 0 continue blood count recover . Patients follow 30 day , 3 6 month , annually 5 year . PROJECTED ACCRUAL : A maximum 42 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm Bcell nonHodgkin 's lymphoma Relapsed refractory disease CD20positive disease Must receive least 1 prior treatment regimen Complete remission prior conventional salvage chemotherapy allow No 25 % lymphoma bone marrow No circulating malignant cell blood smear No CNS involvement lymphoma No HIV AIDSrelated lymphoma PATIENT CHARACTERISTICS : Age Over 17 Performance status ECOG 02 Life expectancy At least 3 month Hematopoietic Platelet count least 100,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Hepatic Transaminases le 2 time normal Renal Creatinine clearance great 50 mL/min Cardiovascular LVEF least 45 % Pulmonary Corrected DLCO least 70 % predict FEV_1 FVC great 60 % Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active infection No serious nonmalignant disease condition would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy More 4 week since prior rituximab recover No prior murine antibodies No prior stem cell transplantation No prior radioimmunoconjugate therapy Chemotherapy See Disease Characteristics More 6 week since prior nitrosoureas mitomycin recover Endocrine therapy No concurrent systemic corticosteroid Radiotherapy Recovered prior radiotherapy No prior external beam irradiation 25 % active bone marrow Surgery More 4 week since prior major surgery recover Other More 3 week since prior anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>